Results 121 to 130 of about 2,116 (170)

Skin Allergy Research Society and Society for Eczema Studies Joint Task Force Guidelines of Care for Management of Atopic Dermatitis for Adults, Children, and Special Populations in India: An Evidence-Based Review and an Expert Consensus. [PDF]

Indian J Dermatol
Dhar S, De A, Rajgopalan M, Godse K, Patil A, Chakraborty D, Pandhi D, Zawar V, Podder I, Chatterjee M, Sarda A, Das A, Girdhar M, De D, Shah B, Panda M, Sharma N, Jagadeesan S, Shankar DSK, Saha A, Banerjee R, Malakar R, Panda S.   +22 more
europepmc   +1 more source

Incident psoriasis in atopic dermatitis: a large-scale cohort study of disease- and treatment-associated risks. [PDF]

Front Immunol
Thaqi F, Bieber K, Kerniss H, Kridin K, Curman P, Ludwig RJ.   +5 more
europepmc   +1 more source

Prescribing Biologic Immune-Modifying Therapies for Patients with a History of Cancer: A Cross-Specialty Review. [PDF]

Curr Oncol
Bowe S, O'Reilly S, Murphy M, O'Mahony A, Harney S, Zulquernain A, Bourke J.   +6 more
europepmc   +1 more source

Long-Term Effectiveness, Safety, and Predictive Factors of Tralokinumab Response in Adolescents with Atopic Dermatitis: Insights from a Real-World Multicenter Cohort. [PDF]

Dermatol Ther (Heidelb)
Villodre Lozano P, Díaz Corpas T, Esteve Martínez A, Millán Parrilla F, Évole Buselli M, Martín Hernández JM, Berbegal de Gracia L, Melgosa Ramos FJ, Auban Pariente J, Sánchez Arraez J.   +9 more
europepmc   +1 more source

The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia. [PDF]

Clinicoecon Outcomes Res
Abu-Shraie N, Al-Sheikh A, Alharbi I, Alanizy L, Alshraim M, Khoshhal SI, AlSalman SA, Alrumaih A, Fasseeh AN, Elezbawy B, Abaza N, Semida A, George M, Amin S, Binamer Y.   +14 more
europepmc   +1 more source

Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition

Allergy: European Journal of Allergy and Clinical Immunology, 2023
Atopic dermatitis (AD) is a chronic, inflammatory, intensely pruritic skin disorder associated with significant patient burden. Interleukin (IL)-13 is a cytokine that acts as a driver of immune dysregulation, skin-barrier dysfunction, and microbiome ...
Thomas Bieber, Emma Guttman-Yassky
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Tralokinumab (Adtralza)

Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +2 more sources